NCT01370070View on ClinicalTrials.gov

MK-2206 in Recurrent Nasopharyngeal Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

December 31, 2016

Study Completion Date

January 31, 2017

Conditions
Recurrent Nasopharyngeal Carcinoma
Interventions
DRUG

MK-2206

200mg weekly repeated q 28 days

Trial Locations (1)

Unknown

Department of Clinical Oncology, Prince of Wales Hospital, Hong Kong

All Listed Sponsors
lead

Chinese University of Hong Kong

OTHER

NCT01370070 - MK-2206 in Recurrent Nasopharyngeal Carcinoma | Biotech Hunter | Biotech Hunter